logo
Plus   Neg
Share
Email

Stock Alert: Supernus Pharmaceuticals Jumps 22% On Quarterly Results, Sales View

Shares of drug maker Supernus Pharmaceuticals, Inc. (SUPN) are rising more than 22% Wednesday morning on upbeat third quarter results. The company has also raised its full-year product sales outlook.

Net earnings in the third quarter were $39.997 million or $0.74 per share compared with $28.86 million or $0.54 per share in the same quarter a year ago due to 52% year-over-year growth in product sales.

Total revenues were $155.14 million compared with $100.03 million in the same quarter a year ago.

Supernus has raised its full-year sales outlook to the range of $500 million to $525 million from $460 million- $500 million provided earlier.

Supernus shares are currently at $22.15 and have been trading in the range of $13.12- $29.36 in the last one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Editors Pick
The U.S. Food and Drug Administration is hastening its efforts to make available more at-home testing options in response to the ongoing COVID-19 pandemic. All At-Home Covid-19 Tests being used now are authorized only for emergency use, and not cleared or fully approved by the FDA. The recent granting of EUA for the Quidel Corp.'s QuickVue At-Home COVID-19 Test is one example. Dollar Tree Inc. (DLTR) Wednesday reported a profit for the fourth-quarter that climbed 309 percent from last year, while Wendy's Co. (WEN) posted a profit that grew about 46.0 percent from the prior year. Dollar Tree has increased its share repurchase authorization by $2.0 billion. Wendy's expects profit for fiscal year 2021 to be below analysts' expectations. Medical devices company Boston Scientific Corp. (BSX) agreed Wednesday to acquire the global surgical business of Israel-based Lumenis LTD from an affiliate of Baring Private Equity Asia (BPEA) for an upfront cash payment of $1.07 billion, subject to closing adjustments. Lumenis is a privately-held...
RELATED NEWS
Follow RTT